ReviewCureus2026
Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is a common malignancy with substantial morbidity, and recent advances in immune checkpoint inhibitors, antibody-drug conjugates, and targeted therapies have improved outcomes across disease stages. Despite these gains, emerging therapies are associated with substantial treatment-related adverse events (TRAEs), including neuropathy, rash, gastrointestinal, ocular, and immune-mediated toxicities, often leading to dose reductions or therapy discontinuation. In this review, we aim to examine the landscape of integrative oncology, its areas of efficacy and uncertainty, and how these therapies may mitigate TRAEs in bladder cancer survivors. Integrative oncology provides patient-centered, evidence-informed approaches to alleviate TRAEs and enhance quality of life. Evidence from randomized trials and systematic reviews suggests that a range of integrative oncology interventions, including acupuncture, cryotherapy, and mind-body therapies, may help temper treatment-related symptoms and improve quality of life among cancer survivors. Nutritional and lifestyle interventions may offer additional benefits, although evidence regarding their safety and optimal implementation remains limited. While most supporting evidence derives from non-genitourinary malignancies, important differences in treatment regimens, patient characteristics, and toxicity profiles limit direct extrapolation to bladder cancer populations, despite overlap in key symptom domains such as fatigue, pain, and peripheral neuropathy. Prospective, disease-specific research is needed to define best practices and integrate multidisciplinary supportive care with conventional therapies. Thoughtful incorporation of integrative oncology may help "thread the needle" between treatment intensity and patient-centered care, with the potential to enhance adherence, survivorship, and the overall patient experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.